CA3238430A1 - Compounds for use in treating gastric cancer - Google Patents
Compounds for use in treating gastric cancer Download PDFInfo
- Publication number
- CA3238430A1 CA3238430A1 CA3238430A CA3238430A CA3238430A1 CA 3238430 A1 CA3238430 A1 CA 3238430A1 CA 3238430 A CA3238430 A CA 3238430A CA 3238430 A CA3238430 A CA 3238430A CA 3238430 A1 CA3238430 A1 CA 3238430A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- pharmaceutically acceptable
- halo
- alkyl
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163280540P | 2021-11-17 | 2021-11-17 | |
| US63/280,540 | 2021-11-17 | ||
| PCT/US2022/050289 WO2023091590A1 (en) | 2021-11-17 | 2022-11-17 | Compounds for use in treating gastric cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3238430A1 true CA3238430A1 (en) | 2023-05-25 |
Family
ID=84887956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3238430A Pending CA3238430A1 (en) | 2021-11-17 | 2022-11-17 | Compounds for use in treating gastric cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250017906A1 (enExample) |
| EP (1) | EP4433051A1 (enExample) |
| JP (1) | JP2024543111A (enExample) |
| KR (1) | KR20240149878A (enExample) |
| CN (1) | CN118488837A (enExample) |
| AU (1) | AU2022390803A1 (enExample) |
| CA (1) | CA3238430A1 (enExample) |
| WO (1) | WO2023091590A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020417293A1 (en) * | 2020-01-03 | 2022-09-01 | Berg Llc | Polycyclic amides as UBE2K modulators for treating cancer |
| WO2024216283A1 (en) * | 2023-04-13 | 2024-10-17 | Bpgbio, Inc. | Microtubule targeting agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10308617B2 (en) * | 2016-06-03 | 2019-06-04 | An2H Discovery Limited | Triazole benzamide derivatives and the compositions and methods of treatment regarding the same |
| CA3112191A1 (en) * | 2018-09-10 | 2020-03-19 | Berg Llc | Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k) |
| AU2020417293A1 (en) | 2020-01-03 | 2022-09-01 | Berg Llc | Polycyclic amides as UBE2K modulators for treating cancer |
-
2022
- 2022-11-17 AU AU2022390803A patent/AU2022390803A1/en active Pending
- 2022-11-17 US US18/711,570 patent/US20250017906A1/en active Pending
- 2022-11-17 KR KR1020247020095A patent/KR20240149878A/ko active Pending
- 2022-11-17 WO PCT/US2022/050289 patent/WO2023091590A1/en not_active Ceased
- 2022-11-17 CA CA3238430A patent/CA3238430A1/en active Pending
- 2022-11-17 CN CN202280082007.5A patent/CN118488837A/zh active Pending
- 2022-11-17 EP EP22839548.9A patent/EP4433051A1/en active Pending
- 2022-11-17 JP JP2024529934A patent/JP2024543111A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4433051A1 (en) | 2024-09-25 |
| US20250017906A1 (en) | 2025-01-16 |
| JP2024543111A (ja) | 2024-11-19 |
| WO2023091590A1 (en) | 2023-05-25 |
| CN118488837A (zh) | 2024-08-13 |
| KR20240149878A (ko) | 2024-10-15 |
| AU2022390803A1 (en) | 2024-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009279944B2 (en) | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | |
| TWI786078B (zh) | 金屬酶抑制劑化合物、抑制金屬酶活性之方法、使用金屬酶抑制劑化合物的方法及醫藥組成物 | |
| EP3209665B1 (en) | Substituted pyrrolotriazine amine compounds as pi3k inhibitors | |
| JP7710215B2 (ja) | ピロール化合物 | |
| CN101426766A (zh) | 用作mek抑制剂的新颖的杂芳基取代的芳基氨基吡啶衍生物 | |
| CN115135325B (zh) | 组合 | |
| US20250017906A1 (en) | Compounds for use in treating gastric cancer | |
| JP2024516353A5 (enExample) | ||
| US20060094728A1 (en) | Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases | |
| JP2020518649A5 (enExample) | ||
| CA3022195C (en) | Compounds for modulating aquaporins | |
| CN114075123B (zh) | 苄胺类衍生物及其制备方法与用途 | |
| JPS5823688A (ja) | グアニジン誘導体、その製法及びこの化合物を含むヒスタミンｈ−２−「きつ」抗性で胃酸の分泌を抑制する医薬組成物 | |
| HUT58330A (en) | Process for producing diazine derivatives and pharmaceutical compositions containing them | |
| JP2025511160A (ja) | ピラゾロピラジノン化合物、その調製のための方法及びその治療的使用 | |
| WO1996015124A1 (en) | Hydrate for medicinal use | |
| JP2022535879A (ja) | Ｐｄｌ１チェックポイント阻害剤としての複素環式免疫調節剤 | |
| JPH08208641A (ja) | 医薬用水和物 | |
| HK1202535B (en) | Estrogen receptor modulators and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250116 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250116 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250425 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250425 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251027 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260107 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260303 |